SABCS 2020: Exploring Safe De-escalation of Breast Cancer Treatment
Several options are available for the treatment of breast cancer, including local therapies such as surgery and radiation therapy,...
SABCS 2020: Should All Breast Cancer Patients Receive Genetic Testing?
Thirty years ago, Mary-Claire King, PhD, FAACR, and colleagues were the first to demonstrate that breast cancer could be genetically inherited....
News from the Cancer Centers: How DCIS Becomes Invasive Breast Cancer
Earlier this year, a study published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR),...
SABCS 2016: Co-director Carlos L. Arteaga, MD, Previews Breast Cancer Symposium
SABCS is a comprehensive scientific meeting that provides the latest information on prevention, diagnosis, and treatment of breast cancer...
Research Highlights from the San Antonio Breast Cancer Symposium 2018
The 41st San Antonio Breast Cancer Symposium, held Dec. 4-8, drew more than 7,500 attendees from more than 90...
SABCS 2016: A New Approach to Understanding Breast Cancer Treatment Resistance
Genomic analysis of estrogen receptor (ER)-positive metastatic breast cancer samples that had become resistant to therapies revealed multiple alterations...
Cancer Genomics: Using Big Data to Advance Breast Cancer Risk Prediction
A new study shows big data can be exploited to develop effective breast cancer prevention strategies and the NIH...
Treating DNA Repair-deficient Breast Cancers
Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers,...
SABCS 2015: Good News for Patients With HER2-positive Breast Cancer
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
SABCS 2016: World’s Largest Breast Cancer Meeting Draws to a Close
Attendees gathered firsthand information on all things breast cancer during the five-day San Antonio Breast Cancer Symposium, which showcased...
Developing a Career in Breast Cancer Research Through the AACR Grants Program
Eddy Shih-Hsin Yang, MD, PhD, associate professor and Regional Oncology Active Research (ROAR) Southeast Cancer Foundation Endowed Chair at...
FDA Approves a New PARP Inhibitor for BRCA-mutant Breast Cancer
In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for...
How Do We Overcome Endocrine Therapy Resistance in Breast Cancers?
Guest Post by Virginia Kaklamani, MD, DSc Co-director of the San Antonio Breast Cancer Symposium (SABCS)
SABCS 2023: Defining and Demystifying Inflammatory Breast Cancer
In 1994, at the age of 40, Ginny Mason, RN, began noticing some concerning differences in the size and...
FDA Approves First Immunotherapeutic for Breast Cancer
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the...
SABCS 2023: POSITIVE Results for Breast Cancer Patients Wanting to Conceive
A breast cancer diagnosis can pose innumerable challenges, and with the average age at diagnosis dropping, the impact of...
Tracking the History of Tucatinib for Breast Cancer Treatment at SABCS
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
Predicting Treatment Response in Patients With HR-positive, HER2-negative Breast Cancer
Studies presented at the 2024 SABCS examined ways to predict responses to treatments for HR-positive, HER2-negative breast cancer.
FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...
Ongoing Progress Against Cancer: New Breast Cancer Therapeutic Approved
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new treatments for cancer continued last week...
Sexual Symptoms and Treatment Adherence After Breast Cancer
Changes to sexual health during breast cancer treatment can impact quality of life and treatment adherence—especially in Black women.
FDA Approves New Treatment for HER2-positive Breast Cancer
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
Endocrine Therapy in Breast Cancer: Improving Clinical Benefits
Most breast cancers express the estrogen and/or progesterone hormone receptors, which fuel tumor growth upon engagement with their respective...
A Youthful Approach: Expanding the Reach of Breast Cancer Prevention
Guest Post by Graham A. Colditz, MD, DrPH Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School...
SABCS 2023: How Do Triple-negative Breast Cancers Evolve?
Charles Swanton, MD, PhD, FAACR, spoke on the role chromosomal instability plays in breast cancer evolution.
FDA Approves New Treatment Option for Breast Cancer
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just...
Studying Blood Vessels to Improve Breast Cancer Outcomes
Josette Northcott, PhD, is exploring the role that blood vessels play in the growth of tumors and the delivery...
Putting the Brakes on Triple-negative Breast Cancer
Breast cancer is the most common cancer among women in the United States and worldwide, with an estimated 2.1 million women diagnosed each year....
SABCS to Showcase Advances in Breast Cancer Treatments
Editor’s note: When the San Antonio Breast Cancer Symposium (SABCS) kicks off next week, researchers will present the results...
FDA Approves a New HER2-targeted Therapeutic for Breast Cancer
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...